Evidence map›Paper›PMID 20961593›Full record

ArticleVirology2010

The identification of HLA class II-restricted T cell epitopes to vaccinia virus membrane proteins.

Richard B Kennedy, Gregory A Poland

Abstract read
In one paragraph

Article in Virology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
0.5field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 21 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Richard B KennedyMayo Vaccine Research Group, Mayo Clinic, Rochester MN 55905, USA. Kennedy.rick@mayo.edu
Gregory A Poland
Mayo Clinic · US

Funding

Vaccines and Therapies Against BotulismU54AI057153 · NIAID · UNIVERSITY OF CHICAGO · PI SHUMAN, HOWARD A · 2003 to 2013
$87.6M
NIAID NIH HHS 2-U54-AI-057153NIAID NIH HHS AI40065NIAID NIH HHS N01 AI040065NIAID NIH HHS U54 AI057153
6 · The paper itself

Abstract

Three decades after the eradication of smallpox, the threat of bioterrorism and outbreaks of emerging diseases such as monkeypox have renewed interest in the development of safe and effective next-generation poxvirus vaccines and biodefense research. Current smallpox vaccines contain live virus and are contraindicated for a large percentage of the population. Safer, yet still effective inactivated and subunit vaccines are needed, and epitope identification is an essential step in the development of these subunit vaccines. In this study we focused on 4 vaccinia membrane proteins known to be targeted by humoral responses in vaccinees. In spite of the narrow focus of the study we identified 36T cell epitopes, and provide additional support for the physical linkage between T and B epitopes. This information may prove useful in peptide and protein-based subunit vaccine development as well as in the study of CD4 responses to poxviruses.

Indexed as

Amino Acid SequenceAntibodies, NeutralizingAntibodies, ViralCross ReactionsEpitopes, T-LymphocyteHeLa CellsHistocompatibility Antigens Class IIHumansInterferon-gammaMolecular Sequence DataSmallpox VaccineSpecies SpecificityT-Lymphocytes, Helper-InducerVaccines, SubunitVaccinia virusVariola virusAntibodies, NeutralizingAntibodies, ViralEpitopes, T-LymphocyteHistocompatibility Antigens Class IIInterferon-gammaSmallpox VaccineVaccines, SubunitViral Envelope Proteins

Identifiers

PMID20961593
PMCPMC2975829
OpenAlexW2033573193

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.